0
A preclinical study offers molecular insight into how activated protein C (APC) may improve the tolerance of aging hearts to reperfusion injury — a potentially adverse effect of treatment for ischemic heart disease
A preclinical study offers molecular insight into how activated protein C (APC) may improve the tolerance of aging hearts to reperfusion injury — a potentially adverse effect of treatment for ischemic heart disease